Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Pre-filled Syringe (solution for injection) 1 X 3 ml |
|
30653 |
Dosage
General accepted dosage is: One subcutaneous injection of Icatibant (3 ml/30 mg), as soon as signs of attack are detected (e.g. swelling of the skin, especially in the area of the face and neck, or increasing abdominal pain).
If the condition is not improved in 6 hours, another 3 ml dose may be administered.
If there is still no improvement, a third dose may be administered after another 6 hours.
No more than 3 doses in 24 hours and no more than 8 injections of Icatibant in one month!
Children and adolescents 2-17 years of age
The recommended dosage of Icatibant Teva is 1 ml up to a maximum of 3 ml, injected subcutaneously (under the skin), according to body weight (one syringe contains 3 ml), as soon as signs of angioedema attack develop (e.g. increased swelling of
the skin, especially in the area of the face and neck, or increasing abdominal pain). See prescribing information for full details.
Indications
Symptomatic treatment of acute attacks of hereditary angioedima (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.
Contra-Indications
Hypersensitivity to the active substance or to any of its excipients.
Special Precautions
See prescribing information for full details.
Pregnancy and Lactation
Pregnancy: The patient should consult the doctor before using this medicine.
Lactation: The patient should not breastfeed for 12 hours after administration of this medicine.
See prescribing information for full details.
